Gilead Sciences, Inc.
—- Market cap
- $178.21B
- Debt
- —
- Cash
- —
Complete market value, debt and cash evidence is required for enterprise value.
Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
FY 2025 · Mkt capMarket cap $178.21B · View financials
Snapshot Sep 11, 2026, 4:00 PM ET
Decision snapshot: GILD stock price at discount vs EPC $143.72 current versus $344.50 implied using P/E multiple.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at EPC's multiple
Implied fair value · at GILD's multiple
Snapshot Sep 11, 2026, 4:00 PM ET
Metric by metric
Where each company leads, and how wide the gap is.
Growth edge
Reported gross margin
Operating income + D&A
Lower is better
Lower P/E
Lower leverage
Statements
Annual statements in reported currencies, with calculations and source evidence.
Values retain reported currencies and share bases. Select a figure to inspect its period, calculation and filing inputs. Differences require compatible units and periods.
Explore enterprise value and market valuation multiples in the valuation sections.
Trendline
Eight period-end years of reported revenue, earnings, and margins. Periods and currencies are shown with the data.
Price framework
USD market cap plus reported borrowing debt, less cash and equivalents. This EV proxy excludes investments, preferred stock and noncontrolling-interest adjustments.
Complete market value, debt and cash evidence is required for enterprise value.
Complete market value, debt and cash evidence is required for enterprise value.
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
GILEAD SCIENCES, INC. · implied price per share
Debt and bridge-cash inputs are required to translate enterprise value into equity value.
EDGEWELL PERSONAL CARE COMPANY · implied price per share
Debt and bridge-cash inputs are required to translate enterprise value into equity value.
Balance sheet health
Inspect reported liquidity and leverage alongside historical financial-health checks.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
AbbVie Inc.
GILD vs ABBV
AMGEN INC
GILD vs AMGN
BRISTOL MYERS SQUIBB CO
GILD vs BMY
Merck & Co., Inc.
GILD vs MRK
PFIZER INC
GILD vs PFE
REGENERON PHARMACEUTICALS, INC.
GILD vs REGN
PROCTER & GAMBLE Co
GILD vs PG
COLGATE PALMOLIVE CO
GILD vs CL
CHURCH & DWIGHT CO INC /DE/
GILD vs CHD
COTY INC.
GILD vs COTY
Cash excludes investments. EBITDA is an operating-income-plus-D&A proxy. Missing borrowing categories remain unavailable; select a value to inspect its inputs.
LLM-powered synthesis
An explanation of the financial evidence. Check its snapshot date against the figures above.
This explanation uses an earlier data snapshot or evidence version. Review its generation date and the current figures, or refresh after signing in.
If you believe GILD can sustain its 34.0% operating margin and 22.3% ROIC, then favor GILD because the stock is priced well below the P/E-implied value while still exhibiting materially better profitability and leverage than EPC.
The P/E-based implied price of $293.46 versus the current price of $125.59 implies 133.7% upside, indicating a large valuation gap on earnings power. GILD also trades below its historical band midpoint and below the DCF range, suggesting the market is pricing it more conservatively than the simple P/E output implies.
Supporting Metrics